Skip to main content

Table 1 Characteristics of the HRT and non-HRT users in the full study cohort (n = 88) and for estrogen-receptor-positive patients (n = 72): Characteristics of the HRT and non-HRT users in the study population

From: Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study

  No HRT HRT  
  All n = 56 ER+ n = 50 All n = 32 ER+ n = 22 P valuea
Age at breast cancer diagnosisb 67.2 ± 11.0   60.1 ± 8.6   0.001
   67.8± 10.8   59.9± 8.7 0.004
Tumor size, mmb 23.0 ± 12.4   26.1 ± 17.1   0.39
   23.4± 12.8   26.2± 18.4 0.47
Affected lymph nodes 40% 21/52   39% 12/31   1.00
   41% 19/46   43% 9/21 1.00
Estrogen receptor-negative tumorsc 11% 6/56   31% 10/32   0.02
   N/A   N/A N/A
Estrogen receptor-protein, fmol/gd 1.8 ± 2.1   0.8 ± 1.5   0.01
   2.0± 2.2   1.2± 1.8 0.11
Progesterone receptor-negative tumorsc 27% 15/56   41% 13/32   0.23
   18% 9/50   23% 5/22 0.75
Recurrence-free survivale 71% 40/56   84% 27/32   0.20
   72% 36/50   86% 19/22 0.24
Elston grade      0.61
      0.27
   Grade I 18% 9/51   23% 7/30   -
   20% 9/45   33% 7/21 -
   Grade II 45% 23/51   50% 15/30   -
   49% 22/45   52% 11/21 -
   Grade III 37% 19/51   27% 8/30   -
   31% 14/45   14% 3/21 -
  1. Values for the ER+ cohort are shown in italics. Means and percentages are shown in bold, standard deviations and counts in plain font. a Calculated via a t-test for age, size, and estrogen-receptor protein, via Fisher's exact test otherwise. b Mean plus/minus standard deviation. c Measured through an immunoassay in which monoclonal antibodies react with the receptor protein in cytosol from tumor homogenates, >0.5 fmol receptor protein/g of cytosol protein was considered as receptor positive. d The immunoassay measurement as described in c above.e Measured as death or distant metastasis within 5 years of diagnosis.